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Human papilloma virus (HPV)-induced cervical cancer is one of themost frequent cancers
in women residing in underdeveloped countries. Natural compounds like polyphenols
continue to be of scientific interest as non-toxic effective alternative treatments. Our
previous work showed the efficacy of two polyphenols, resveratrol, and pterostilbene
on human HeLa cells. Here we explored the in vitro anti-cancer activity and in vivo
anti-tumor potential of these two structurally similar compounds on HPV oncogene E6
and E7 positive murine TC1 cells. In vitro analysis confirmed the cytotoxic potential of
both resveratrol and pterostilbene compounds with each having a low IC50 value and
each showing the ability to downregulate viral oncogene E6. Further in vivo studies
on TC1 tumors developing in mice indicated that treatment with either resveratrol or
pterostilbene can significantly inhibit tumor development, with both compounds capable
of downregulating E6 and VEGF tumor protein levels. Interestingly, the decrease in
tumor size in pterostilbene was associated with tumor cell apoptosis, as indicated
by an upregulation of activated caspase-3 whereas in resveratrol-treated mice it was
accompanied by arrest of cell cycle, as indicated by a downregulation of PCNA. Thus,
resveratrol and pterostilbene can serve as potential antineoplastic agents against HPV
E6+ tumors and may suppress tumor growth via two different mechanisms.
Keywords: HPV E6 positive cervical cancer, natural product, resveratrol, pterostilbene, PCNA, caspase-3, VEGF,
in vivo
INTRODUCTION
Human papilloma virus (HPV) is responsible for almost all cervical cancer incidences (1). High
risk HPV types are also responsible for other types of invasive malignancies including head and
neck cancers, oropharyngeal cancers, and other anogenital cancers. Cervical cancer is the fourth
most common cancer in women and accounts for almost 7.5% of female cancer deaths worldwide
(2). With current screening and vaccination programs, the rate of cervical cancer has decreased
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in developed countries, however the major burden lies within
developing countries due to lack of awareness and resources
(3, 4). Every year more than 500,000 new cases of cervical cancer
are reported, with the majority originating from developing
countries. Etiologically, prolonged infection with HPV has
been the primary agent associated with cancerous progression.
Moreover, HPV16 and HPV18 are the two most prevalent high-
risk strains that are responsible for most of the cervical cancers
diagnosed. Sustained expression of two oncoproteins, E6 and E7,
play an essential role in the maintenance of these malignancies
(5). All of the current treatment regimens for metastatic
cervical cancer (radiation, surgery, and chemotherapy) (6) are
associated with deleterious side effects (7–9). Advancements in
cancer prevention and treatment have unfortunately failed in
significantly decreasing cervical cancer mortality in developing
countries, often because of the high costs associated with each.
Due to a growing need for effective low-cost cervical cancer
therapy with no detrimental side effects, naturally occurring
dietary polyphenols, that have known anti-cancer properties,
have continued to be of great interest.
Stilbenes are a group of naturally occurring polyphenols
that have a diphenylethylene nucleus and are synthesized in
plants as a defense mechanism (10). Resveratrol, commonly
found in specific fruits including grapes and mulberries, is
the most well-studied stilbene compound with considerable
evidence supporting its anti-cancer properties (11). Another
such compound with a stilbene core that has gained much
attention in the recent years is pterostilbene, a structural analog
of resveratrol. Several studies indicate that pterostilbene has
a higher bioavailability than resveratrol and like resveratrol is
nontoxic to humans even at high doses (12, 13).Studies using
pterostilbene on normal liver cells and non-cancerous breast
epithelial cells show specificity against cancerous cells without
causing any acute toxicity to normal cells (14, 15).Clinical trials
in humans have shown that both these compounds are nontoxic
to normal cells and are well-tolerated (13, 16). Both resveratrol
and pterostilbene have shown much potential in inhibition of
different types of cancer cells including colon cancer, stomach
cancer prostate cancer, and breast cancer (17, 18). Few studies
have utilized in vivo tumor models to determine the effectiveness
of these two compounds and these involved pancreatic, colon,
and liver cancer (11, 19–23). Previous studies by our team
using these two compounds have shown that both resveratrol
and pterostilbene are cytotoxic to HPV18 HeLa cells in a dose
dependent manner (4). The compounds were able to inhibit cell
cycle progression, decrease migration at lower concentrations
and also induce apoptotic cell death at higher concentrations in
vitro (4). Like our previous finding, other studies also indicate
that pterostilbene might have superior efficacy in combating
cancer (4, 24). We were, to the best of our knowledge, the first
group to report that these polyphenols were able to specifically
target the essential oncoprotein E6 and induce cervical cancer cell
death (4).
In the current study we set out to examine the efficacy of
both these compounds in vivo. For this purpose, we used a
cervical cancer murine model injected with TC1 cells. These
cells were originally derived from mouse primary lung epithelial
cells transformed with three oncogenes: HPV16-E6, -E7, and c-
Ha-Ras. TC1 tumor models have been widely used as a model
for cervical cancer and have been used to study in vivo effects
of several therapeutic strategies (25–27). Unlike resveratrol
there are very few studies on the effects of pterostilbene in
cervical cancer. Furthermore, there is very little known about
the anticancer effects of resveratrol and pterostilbene when
compared in vivo. In this study comprehensively analyzed the
efficacy of these two polyphenols in HPV-oncogene positive
tumors and explored the therapeutic possibility of these natural
compounds in vitro and in vivo. Our findings show for the
first time that these compounds can significantly reduce the
size of HPV-oncogene positive TC1 tumors. Importantly, both
compounds significantly reduced HPV E6, the oncoprotein
driving tumor formation. Only a short treatment cycle of 5
days was sufficient to see a significant antitumor potential of
resveratrol and pterostilbene. We propose that this antitumor
efficacy is dependent on two different mechanisms where
resveratrol playing a vital role in arresting tumor growth evident
by a significant reduction of proliferating cell nuclear antigen
(PCNA) and pterostilbene largely causing cell death in tumors
by activating apoptotic caspase-3. These results show for the
first time that stilbene compounds resveratrol and pterostilbene
show a robust antitumor potential both in vitro and in vivo in
HPV E6 positive cancers and are promising candidates as natural
anticancer therapeutics.
MATERIALS AND METHODS
Cell Culture
TC-1 mouse cells were procured from the lab of Dr. T.C. Wu at
Johns Hopkins University. TC-1 cells were derived from primary
lung epithelial cells of C57BL/6 mice after co-transformation
with HPV16-E6, HPV16-E7, and c-Ha-Ras oncogenes (25). The
cells were maintained in Dulbecco’s Modified Eagle Medium:
Nutrient Mixture F-12 (DMEM/F-12) (HyClone, GE Healthcare
Life Sciences, Manassas, VA, USA), supplemented with 10% fetal
calf serum (HyClone, GE Healthcare Life Sciences) with 0.1%
Penicillin-Streptomycin Solution (HyClone). Cells were cultured
in a humidified incubator at 37◦C incubator and 5% CO2.
Determination of IC50 Using WST-1 Assay
Four thousand TC-1 cells were plated on 96-well plates
and cultured for 24 h. Resveratrol (Acros, #430075000) or
pterostilbene (TCI, #P1924) were serially diluted from 5 to
100µM in DMEM/F-12 supplemented with 1 × insulin-
transferrin-selenium (ITS; Invitrogen). Treatment was carried
out with the dilutions (in triplicate) for 72 h after which time a
WST-1 (Water Soluble Tetrazolium salt-1; Clontech, Mountain
View, CA, USA) cell viability assay was performed. The medium
was aspirated after treatment and rinsed three times with 1 ×
Phosphate Buffered Saline (PBS). After rinsing, 80 µL of a 10%
WST-1 fresh solution was prepared in DMEM and subsequently
added to each well. The plate was then incubated for 1 h at
37◦C to get a color reaction. The absorbance was recorded at
440 nm using a 96-well spectrophotometer. The results were then
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FIGURE 1 | Resveratrol and pterostilbene are cytotoxic to TC1 cells. (A) Brightfield analysis of TC1 cells untreated (Control) or treated with 10, 20, and 30µM of
resveratrol (Res) or pterostilbene (Pte). . (B) IC50 values generated using a water soluble tetrazolium salt-1 (WST-1) assay after 72 h of exposure to resveratrol or
pterostilbene shows that pterostilbene (Bi) is more cytotoxic than resveratrol (Bii) (IC50 = 15.61µM vs. IC50 = 34.46µM; p < 0.0001, n = 3). (Biii) Bar graph
represents comparative data showing the difference in viable cells treated with resveratrol or pterostilbene at 20 or 40µM (mean ± S.E.M.; *p < 0.05, n = 3).
analyzed using GraphPad Prism 7 software to obtain the IC50
using a standardized method (4).
Immunocytochemistry
TC-1 cells were cultured on 8-well chamber slides for 48 h
prior to immunocytochemistry. The cells were then untreated
(control) or treated with resveratrol (30µM) or pterostilbene
(30µM) for 48 h prior to immunocytochemical detection of
E6. The dilutions of resveratrol and pterostilbene were done
in serum-free DMEM/F-12 containing 1% supplement (ITS;
insulin, transferrin, selenium; Gibco BRL, Grand Island, NY,
USA). After treatment, cells were fixed in 4% paraformaldehyde
at room temperature. After rinsing with 1 × PBS cells were
permeabilized and blocked with 10% goat serum, 2% bovine
serum albumin, and 0.5% Triton X-100 in PBS for 1 h. This
was followed by overnight incubation with E6 antibody (sc-
460; Santa Cruz Biotechnology) in blocking buffer. After probing
with primary antibody, the cells were washed and incubated
with Fluorescein isothiocyanate (FITC) conjugated secondary
antibodies for 3 h, followed by incubation with 4
′
,6-diamidino-
2-phenylindole (DAPI) (10µg/mL). After washing with 1X
PBS the slides were mounted with coverslips and cell images
were acquired using a Leica SP2 confocal microscope. Images
of randomly chosen field from different treatment wells were
taken and used for quantification. ImageJ was used to measure
the fluorescence intensity and cell counting. The fluorescence
intensity of E6 antibody was normalized to DAPI intensity (blue).
TC-1 Mouse Model Generation
and Treatment
Fifty thousand TC-1 cells harvested from actively growing
cultures were injected subcutaneously in the nape of the neck
of female C57BL/6 mice, which were ∼2–3 months old. This
tumor model has been standardized and used in previous studies
(27, 28). Once palpable tumors were formed (in ∼15–20 days)
treatment cycles was initiated. The mice were anesthetized
by intraperitoneal injection of 100 mg/kg ketamine and 10
mg/kg xylazine. A power test was used to determine the
minimum number of mice (n) to be used for the study to
achieve a confidence level >90% (29). Treatment involved
the mice being randomly divided into three groups, control,
resveratrol, and pterostilbene–with each group containing 5
mice. Tumors were marked into four quadrants and 10 µl
of the 1mM resveratrol or 1mM pterostilbene was injected
into each quadrant intralesionally for 5 consecutive days. We
approximated the average initial tumor volume to be around 0.3–
0.5ml using a caliper to measure approximate tumor diameter
(27). We administered 10 µl treatment in 4 quadrants such that
the expected internal concentration is above 80µM (lethal dose
for both resveratrol and pterostilbene). The control group of
mice were subjected to 1 × PBS injections also for 5 consecutive
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FIGURE 2 | Viral oncoprotein E6 gets downregulated in TC1 cells treated with resveratrol or pterostilbene. (A) TC1 cells immunostained and probed for E6
oncoprotein (green) and counterstained with nuclear stain DAPI (blue). Cells treated for 48 h with resveratrol (30µM) or pterostilbene (30µM) shows pterostilbene has
a more significant downregulation of E6 protein expression as compared to resveratrol and control. (B) Bar graph indicates the percent decrease in E6 expression in
treated TC1 cells as compared to control untreated TC1 cells. The graphs represent data from three independent experiments (mean ± S.E.M.; *p < 0.05).
days. After the completion of the treatment cycle the mice
were sacrificed and the tumors were excised. Tumor volumes
for the excised tumors were measured using a caliper and
volumes were calculated as previously mentioned (27). Tumors
were then fixed and processed for immunohistochemistry. All
mouse experiments were performed according to NIH guidelines
for animal use and approved by the Institutional Animal Care
Committee (IACUC) of the College of Staten Island (CUNY)
(approval # 11–008).
Immunohistochemistry
Tumor sections that were taken from the approximate center
of the tumor were randomly selected from each group for
immunohistochemical analysis. The sections were first subjected
to antigen-retrieval using formamide: 2 × SSC at 55◦C for 2 h
followed by two PBS washes. The sections were then blocked
with 3% goat serum or 10% rabbit serum for 2 h and then
treated overnight with primary antibodies: anti-E6 antibody (sc-
460; Santa Cruz Biotechnology) or VEGF (P-20; Santa Cruz
Biotechnology) or PCNA (#2586 Cell Signaling Technology) or
Cleaved Caspase-3 (Asp 175) (#9661; Cell Signaling Technology).
The antibodies were diluted in 2% goat serum or 2% rabbit serum
and 0.1% Triton X in PBS. The sections were washed with PBS
after the primary treatment and then probed with the secondary
antibody. For E6 primary antibody the secondary antibody used
was Alexa Fluor-488 goat anti-mouse (Invitrogen) and for VEGF
primary the secondary antibody used was Alexa Fluor-488 rabbit
anti-goat (Invitrogen). Sections were also stained only with the
secondary antibodies as a negative control for the experimental
setup. After overnight incubation with secondary antibody at 4◦C
the sections were washed and stained with nuclear stain DAPI
(10µg/ml) for 15min at room temperature. The sections were
then mounted on a slide with Gold anti-fade mounting fluid.
Confocal Images of the immunostained sections were taken using
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FIGURE 3 | Inhibition of tumor growth in E6+ tumor bearing mouse. (A) Schematic representation of mouse TC1 tumor in vivo tumor generation and subsequent
treatment cycle. TC1 cells were injected subcutaneously in 15 mice followed by daily palpations. After 15–20 days, when the tumors became apparent mice were
divided into three groups of five and treated intralesionally with either PBS (control), resveratrol or pterostilbene for 5 consecutive days. After 5 days the mice were
sacrificed, and the tumor excised. (B) Tumors excised from the three representative groups, displayed for imaging with corresponding volume (ml). In both treatment
group tumors show marked decrease in tumor size compared to control. (C) Bar graph shows percent reduction in tumor size in mice treated with resveratrol or
pterostilbene in comparison to control tumor. Tumor size reduction is significant in the treated groups. The graphs represent data from 5 mice from each group (mean
± S.E.M.; *p < 0.05).
a Leica SP2 microscope from multiple randomly chosen fields of
multiple sections.
Image Quantification and Data Analysis
All images taken were quantified using ImageJ software. The
empirical data obtained from all experiments were analyzed using
GraphPad Prism 7 software.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism R©7
(GraphPad Software, Inc., La Jolla, CA, USA). The mean and
standard error mean was obtained for each of the groups. One-
way ANOVA with post-hoc Tukey test was used to compare the
data sets and determine the significance as performed in previous
publication (4). p < 0.05 was considered as significant.
RESULTS
Resveratrol and Pterostilbene Are
Cytotoxic to TC1 Cells
Based on the findings of our previous studies on HeLa cells
showing the cytotoxic potential of resveratrol and pterostilbene
(4), we wanted to determine their anticancer efficacy on HPV-
E6-positive mouse TC1 cells. Brightfield images were taken after
48 h of treatment with different concentrations of resveratrol
or pterostilbene to see their cytotoxic potential relative to
untreated control cells (Figure 1A). A qualitative analysis of the
images indicates that compared to control untreated cells, both
resveratrol and pterostilbene show significant cytotoxicity, with
pterostilbene showing more cell death and cytoplasmic blebbing
than resveratrol after 48 h. These comparative effects are visible
even at low concentrations of 10µM and apoptotic cell numbers
increased in a dose dependent manner for both treatment
groups. Analytically we ascertained the IC50 concentrations of
these two polyphenols by performing WST-1 assays for cell
viability (Figure 1B). The results showed the IC50 of resveratrol
to be 34.46µM (Figure 1Bi) while that of pterostilbene was
>2-fold less at 15.61µM (Figure 1Bii). These IC50 values were
significantly different from each other (p < 0.0001) and confirm
the superior cytotoxicity of pterostilbene over resveratrol in vitro
on TC1 cells (Figure 1B).
E6 Oncoprotein Gets Downregulated by
Resveratrol and Pterostilbene in vitro
To investigate whether the expression of HPV viral oncoprotein
E6 was attenuated by either polyphenol treatments, we used
immunocytochemical techniques to probe for protein levels in
TC1 cells. Using the results from the brightfield images and
the IC50 values we selected a supra IC50 concentration at 48 h
for treatments (30µM). Immunocytochemical analysis indicated
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that cells treated for 48 h with pterostilbene but not resveratrol
had significantly lower E6 levels when compared to control (81
vs. 12%, Figures 2A,B; p < 0.0001). Although E6 expression
levels in resveratrol treated cells were downregulated by 12%
compared to control this down regulation was not statistically
significant (Figure 2B; p = 0.1838). The downregulation of
E6 levels by pterostilbene was also significantly different
than resveratrol (p < 0.0002). Therefore, our results show
that in vitro pterostilbene is more potent in downregulating
the essential oncoprotein E6 in TC1 cells as compared to
resveratrol treatment.
Reduction of Tumor Size in Mouse Model
by Resveratrol and Pterostilbene
To find out the potency of these two polyphenols in vivo we
generated mouse tumors by implanting TC1 cells subcutaneously
in syngeneic C57Bl/6 female mice. After palpable tumors were
formed mice were randomly divided into 3 groups. We treated
the mice intralesionally (10 µl in each of the 4 quadrants of
individual tumor) with 1mM resveratrol or 1mM pterostilbene
for 5 consecutive days. Control group mice received PBS
injections. The dosage was selected such that the intratumoral
concentration of the compounds would be expected to be above
lethal dose (calculated from the IC50 curve) in both treatment
groups. Treatment was carried out for a period of 5 days
to comply with ethical standards and avoid morbidity. After
completion of the treatment cycle the tumors were excised,
the volume of the tumors were measured using a caliper and
then volumes were calculated as mentioned previously (27)
(Figure 3A).The tumor size was drastically lower than the
untreated tumors for both the treatment groups (Figure 3B).
Tumor size is 16.48% (±1.99) in resveratrol treated groups
and 28.06% (±6.32) in pterostilbene treated groups. The radical
decrease of tumor load clearly shows the high anticancer and
tumor inhibitory potential of both resveratrol and pterostilbene
(Figure 3B). Tumor volumes were measured and graphed
showing that the tumor size decreased by 83.5% in resveratrol
treated groups and by 72% in pterostilbene treated groups
(Figure 3C) as compared to control. The reduction of size for
both treatment groups is significant compared to control (p <
0.0001) but not significantly different from each other.
Reduction of E6 Oncoprotein Level in vivo
by Resveratrol and Pterostilbene
To determine if E6 is downregulated in the resveratrol and
pterostilbene treated tumors we used immunohistochemistry. E6
protein levels can be seen to be very high in control untreated
tumor sections (Figure 4A). However, the treated groups show
much lower expression of E6 indicating that both the polyphenols
can target E6 for downregulation. In control tumors almost all the
cells are E6 positive with high level of expression. In resveratrol
and pterostilbene treatment not only are the number of E6
positive cells reduced but also the level of protein expression in
these cells is lower. The fluorescence intensities of the tumor
sections were compared and graphed (Figure 4B). Resveratrol
has an intensity of 20.6 ± 5.1 (79% decrease vs. control) and
FIGURE 4 | E6 expression is reduced in mouse tumors. (A) Tumor sections
immunostained with E6 antibody shows decreased E6 protein (green) in mice
treated with resveratrol or pterostilbene when compared to control untreated
tumors. Sections were counterstained with DAPI (blue). Scale bar: 47.62µm.
(B) Graph indicates the significant reduction of E6 expression levels in
resveratrol or pterostilbene treated tumors in comparison to control tumors
sections (mean ± S.E.M.; *p < 0.05).
pterostilbene has a total intensity of 10.5 ± 2.2 (89% decrease
vs. control). These finding indicate that both polyphenols can
significantly downregulate the expression of E6 inmurine tumors
compared to untreated tumors (p < 0.0001) and corroborate the
tumor volume reduction data.
Downregulation of PCNA Protein in vivo by
Resveratrol and Upregulation of Cleaved
Caspase 3 by Pterostilbene
To understand the underlying mechanism(s) of tumor inhibition
by these two polyphenols we analyzed by immunohistochemistry
the apoptotic marker, activated caspase-3 (Figures 5A,B), and
the proliferation marker, PCNA (Figures 5C,D). These results
indicated that tumors treated with pterostilbene have a significant
amount of activated caspase-3 protein compared to resveratrol
and control tumors (Figure 5A). The percentage of apoptotic
cells represented graphically in Figure 5B indicates that in vivo
resveratrol treatment does not appear to activate the process of
caspase-3-mediated apoptosis whereas pterostilbene treatment
significantly increased this pathway (16.34 vs. 2.72%; p< 0.0001).
The difference in activation of caspase-3 by pterostilbene is
also significantly greater than tumors treated with resveratrol
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(p < 0.0001). In contrast, resveratrol treated tumors showed a
significantly lower expression of PCNA compared to untreated
and pterostilbene treated tumors (Figure 5C). The percentage of
cells expressing PCNA reduced by 75.5% in resveratrol treated
tumors compared to control (25.26 ± 10.5 vs. 100 ± 5.6; p
< 0.0004). Moreover, the downregulation of PCNA positive
cells by resveratrol is significantly different than tumors treated
with pterostilbene (p < 0.0006). Taken together these results
show that resveratrol targets downregulation of proliferation
(Figures 5C,D) whereas pterostilbene activates apoptosis in TC1
tumors, with both polyphenols providing a substantial decrease
in tumor growth compared to control untreated tumors.
Downregulation of VEGF Protein in vivo by
Resveratrol and Pterostilbene
E6 is known to upregulate VEGF expression in HPV positive
tumor cells (30) therefore, we analyzed VEGF expression as
a biomarker for E6 downregulation. Immunohistochemical
analyses of tumor tissue showed that VEGF expression is
lowered by the treatment of either resveratrol or pterostilbene
(Figure 6A). Control tumor sections show a high expression of
VEGF whereas treatment with either resveratrol or pterostilbene
lowered the protein levels. The reduction is seen ubiquitously
throughout the tumor sections in both the treated groups. The
graph ascertains the level of downregulation with resveratrol
showing a reduction to 60.5% (60.57 ± 3.13) and pterostilbene
to 66.8% (66.88 ± 2.8) compared to control (100%) (Figure 6B).
Both treatments were able to significantly downregulate the
expression of VEGF protein (p < 0.0001).
DISCUSSION
In the current study we have elucidated for the first time the
efficacy of stilbene compounds, resveratrol and pterostilbene
using an in vivo murine E6 positive tumor model. We first
demonstrated that in vitro pterostilbene shows a higher efficacy in
eliminating E6-positive TC1 cells, when compared to resveratrol
(Figure 1). It is important to note that both compounds
show significant cytotoxicity when compared to untreated
cells. Further in vitro analysis revealed that pterostilbene
targeted significant downregulation of the HPV oncoprotein
E6 (Figure 2), which drives these cells to form tumors in
vivo. In comparison, cells treated with resveratrol exhibited less
E6 compared to untreated controls, but the results were not
statistically significant (Figure 2).
Our in vivo studies using TC1 murine model showed that
both pterostilbene and resveratrol treatment cause a significant
decrease of tumor size. Upon further examination we were able
to demonstrate that pterostilbene causes significant apoptosis in
the tumors whereas resveratrol plays a major role in arresting
the growth of these tumors. Therefore, this study shows for the
first time, to the best of our knowledge that resveratrol and
pterostilbene can exhibit antitumor activities and reduce tumor
load by two distinct mechanisms; resveratrol through cell cycle
arrest (down regulation of PCNA) and pterostilbene through
apoptosis (upregulation of caspase-3; Figure 5). Delving deeper
into the possible targets of these polyphenols we found that
the angiogenic protein VEGF is significantly reduced by both
these natural compounds (Figure 6). Our study, for the first
time, elucidates that both resveratrol and pterostilbene show
anticancer potential in vivo by downregulating HPV E6.
We first confirmed the cytotoxic potential of resveratrol
and pterostilbene on TC1 cells in vitro. Our results showed
that pterostilbene is two-fold more potent than resveratrol in
eliminating TC1 cells (Figure 1). This corroborated our previous
findings on HeLa cells where we had seen a similar pattern of
IC50 with pterostilbene showing superior efficacy than resveratrol
(4). HPV E6 oncoprotein is known to play an essential role in
cervical carcinogenesis. Both E6 and E7 protein expression is
required for continuous cell proliferation and metastasis. Studies
have confirmed that eliminating E6 oncoprotein pushes the cells
toward cell growth arrest and apoptosis (31, 32).Several efforts
are being made to use anti-E6 strategies to induce HPV cancer
cell death (33, 34). Our previous study on HeLa cells showed
that although both resveratrol and pterostilbene downregulate E6
expression, pterostilbene has higher inhibitory efficacy compared
to resveratrol (4). In the current study we see a similar trend
in E6 level suppression in vitro, with pterostilbene treatment
showing greater suppression of E6 protein levels than resveratrol
treatment (Figure 2). This increased efficacy of pterostilbenemay
be attributed to its structural stability. The methoxy group in
pterostilbene makes it more lipophilic and more bioavailable
than resveratrol (35, 36). Pharmacokinetic studies have also
established the superior bioavailability of pterostilbene over
resveratrol (36, 37).
Our current and previous studies using TC1 cells and
HeLa cells, respectively, confirmed the anticancer potential of
resveratrol and pterostilbene in vitro. Here our aimwas to further
validate these compounds as promising cervical cancer therapies
and tomore importantly evaluate their anticancer potential using
in vivo model of cervical cancer. To achieve this goal, we used
TC1 cells which are E6, E7, and c-Ha-Ras positive transformed
mouse epithelial cells. Due to a lack of cervical cancer mouse
models, TC1 cells have been widely used for creating E6-positive
mouse tumors to test vaccines and other therapies (25, 27, 38).
Several studies have utilized this model to understand the role the
immune system and microenvironment in HPV cancers and also
study immunotherapeutic strategies (28, 39, 40). Combinatorial
studies using natural compounds including resveratrol has been
successfully tested on TC1 tumormodels (27, 28). However, there
has been no study that has investigated the potential of resveratrol
and pterostilbene individually on a cervical cancer model.
To evaluate the efficacy of these polyphenols in vivo, we
established TC1 tumors in C57BL/6 mice and subjected them
to intralesional treatment with 5 daily injections of 40 µl of
resveratrol (1mM) or pterostilbene (1mM). At the end of
the treatment cycle, tumors treated with either resveratrol or
pterostilbene were significantly smaller than those treated with
1 × PBS alone (Figure 3). Resveratrol was able to reduce
tumor size by an average of 83% while pterostilbene reduced
tumor size by an average of 72%, when compared to control.
The difference in tumor reduction between resveratrol and
pterostilbene was not significant, which was unexpected given
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FIGURE 5 | Upregulation of activated caspase 3 and downregulation of PCNA expression in mouse tumors. (A) Tumor sections immunostained with cleaved caspase
3 antibody shows elevated protein levels (green) in mice treated with pterostilbene when compared to control untreated tumors. Resveratrol treated tumors did not
show any significant change in caspase 3 expression. Sections were counterstained with DAPI (blue). Scale bar: 47.62µm. (B) Graph indicates the significant
increase of Cleaved caspase 3 expression levels in pterostilbene treated tumors in comparison to control tumors sections (mean ± S.E.M.; *p < 0.0001). (C) Tumor
sections immunostained with PCNA protein (green) and counterstained with nuclear stain DAPI (blue). Resveratrol treated tumors display a significant decrease in
PCNA expression compared to control sections. Pterostilbene treated tumors show similar PCNA levels as control. Scale bar: 47.62µm. (D) Quantitative analysis of
PCNA expression shows a significant change in resveratrol treated tumor sections (mean ± S.E.M.; *p < 0.0004; The two treatment groups show significant
differences in PCNA expression (p < 0.0006).
the potency of pterostilbene to more efficiently reduce E6 in
vitro (Figure 2). When we assessed the E6 protein levels by using
immunohistochemistry on tumor tissue we found resveratrol
and pterostilbene both significantly inhibit E6 expression when
compared to PBS (control) treated tumors, although resveratrol
downregulated E6 to a lesser extent (Figure 4).
Several in vivo studies show that resveratrol has anticancer
properties against breast cancer, colorectal cancer, and liver
cancer in rat and mouse tumor models (23). In humans,
resveratrol is well-tolerated with low toxicity andmultiple clinical
trials have proven the beneficial effects of this polyphenol
on colorectal cancer and breast cancer to name a few (11).
Pterostilbene has gained a lot of attention in recent years as a
more potent bioavailable analog of resveratrol. Clinical trials also
indicate the low toxicity of pterostilbene up to 250mg/day dosage
(13). Pterostilbene has shown potential in abrogating several
cancers like breast and colon cancer in animal models (18).
Although preclinical studies show the potency of pterostilbene
on several types of cancers, there is a lack of large scale clinical
studies (35).The in vivo efficacy of these two polyphenols on
cervical cancer has also not been substantially explored. Several
in vivo studies have explored using intra cervical treatment as
a potential mode of treatment and we have tried to explore the
maximum potential of resveratrol and pterostilbene at a specific
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FIGURE 6 | Downregulation of VEGF expression in mouse tumors. (A) Tumor
sections immunostained with VEGF protein (green) and counterstained with
nuclear stain DAPI (blue). Both resveratrol and pterostilbene treated tumors
display a significant decrease in VEGF expression compared to control
sections. Scale bar: 47.62µm. (B) Quantitative analysis of VEGF expression
shows a significant change in treated tumor sections (mean ± S.E.M.;
*p < 0.05).
dosage against HPV E6 positive cancer (41–44). Previous studies
by our team have found that intravaginal application of natural
compound formulation has no adverse effects and can possibly
decrease HPV positive tumor load (45). Our studies bring to light
the strong potential of resveratrol and pterostilbene to reduce
tumor growth in a mouse cervical cancer model. The results
show support toward clinical trials investigating resveratrol and
pterostilbene in late stage cervical cancer, when local resection
of tumor is not effective or as a possible preventative treatment
to those individuals with chronic HPV cervical infection in the
absence of tumor.
Suppression of apoptosis and uncontrolled proliferation
are major steps essential for progression and metastasis of
cancer (31). Resveratrol and pterostilbene are known to have
proapoptotic, chemo preventative, and anticancer properties
(46). Keeping in mind the extensive reduction of tumor
growth seen in vivo we wanted to explore if resveratrol and
pterostilbene trigger the apoptotic pathway. Several in vitro
studies have shown that both these polyphenols can induce
apoptosis in several cancer cell lines including cervical cancer
(4, 24, 47, 48). Our result showed that pterostilbene but not
resveratrol is able to induce considerable apoptotic cell death
in TC1 tumor cells in vivo. The upregulation of pro-apoptotic
activated caspase-3 by pterostilbene was significantly higher
than untreated tumors whereas, resveratrol showed barely any
change (Figure 5A). The difference in caspase-3 activation
between the two treatments was statistically significant and it
was surprising to us given resveratrol’s potency to induce cell
death in our in vitro studies. We then further analyzed the
growth inhibitory effects of these two polyphenols in tumor
tissue by performing immunohistochemistry for PCNA. PCNA
is known to be highly up regulated in HPV positive cancers
(49) and is known to play a major role in cancer neoplasia
(50). Our results showed that resveratrol, but not pterostilbene,
can drastically downregulate PCNA expression in TC1 tumors.
The untreated and pterostilbene treated tumors had similar
PCNA expression patterns (Figure 5B). Our findings elucidate
that resveratrol and pterostilbene reduce tumor size by possibly
two different mechanisms, resveratrol by downregulating growth
and pterostilbene by upregulating death of tumor cells. It is
known that pterostilbene is more bioavailable than resveratrol
in vivo (36, 51). In our studies on HeLa cells we had seen
that resveratrol can cause cell cycle arrest at a sub IC50
concentration (4). We think that possibly pterostilbene being
more bioavailable is absorbed more in the tumor resulting
in a higher internal concentration compared to resveratrol
which being less bioavailable results in a lower intra-tumoral
concentration. Based on our previous study and current results
we hypothesize that resveratrol with a lower tumor concentration
induces cell cycle arrest whereas pterostilbene remains at a
high concentration within the cell and thus triggering apoptosis.
Moreover, cells of the tumor microenvironment may respond
differently to the two polyphenols to cause this similar tumor
reduction (28).
HPV E6 is an oncoprotein which has several important
targets that can affect cellular pathways leading to oncogenesis
(52). VEGF overexpression is of supreme importance in cervical
cancer biology (30). Studies have shown that HPV E6 is
associated with activating the promoter for VEGF gene in cervical
cancers (30). VEGF is known to induce angiogenesis, tumor
cell proliferation, and plays a vital role in cervical neoplastic
progression (53). Current therapies for recurrent cervical
neoplasia include the usage of bevacizumab (Avastin) which
is an anti-VEGF antibody (54). Unfortunately treatment with
Avastin is associated with several serious side effects including
hemorrhaging (54). Previous studies have shown that resveratrol
can inhibit angiogenesis by targeting HIF-1α and VEGF in
cervical cancers cells (54). Pterostilbene has also shown anti-
angiogenic properties in skin and lung cancers (18). However,
there have been no studies evaluating pterostilbene’s efficacy
in cervical cancer. In the current study we found that both
resveratrol and pterostilbene can downregulate VEGF expression
and therefore should be further evaluated as alternative or
complement to current anti-angiogenic cervical cancer therapies.
Both treatment groups can downregulate VEGF expression
equally (Figure 6). As VEGF is an important target for therapy
our findings establish the therapeutic potential of resveratrol
and pterostilbene in HPV positive cancers. Further studies
are required to fully understand the underlying mechanism
of action of these two polyphenols and delineate the possible
downstream targets triggered by E6 downregulation that elicit
this tumor reduction.
Thus, our findings show the potency of resveratrol and
pterostilbene on TC1 tumors by downregulating the oncoprotein
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E6, which drives TC1 tumor growth. The robust capability
of these natural plant compounds to arrest and eliminate E6
positive tumor cells is promising for those researchers looking
for alternative therapies to cervical cancer or for a better
understanding of E6 oncogene activity.
CONCLUSIONS
Cervical cancer remains prevalent in many countries where anti-
HPV vaccines and preventative preneoplastic assessments are
not routinely provided. Here we provide strong evidence that
the natural compounds pterostilbene and resveratrol are effective
in drastically shrinking a cervical cancer tumor model in vivo
when injected directly into the tumor. Further studies, analyzing
our tumor model treated with systemic injections of these
compounds is the next appropriate step. Given these compounds
are well-tolerated in humans, they may provide clinicians with a
viable therapy in the treatment of cervical cancer, especially when
current therapies are not available because of the high cost to
the patient.
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